{"id":"NCT04718103","sponsor":"GlaxoSmithKline","briefTitle":"A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype","officialTitle":"A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-04","primaryCompletion":"2024-04-11","completion":"2024-04-11","firstPosted":"2021-01-22","resultsPosted":"2024-11-29","lastUpdate":"2024-11-29"},"enrollment":397,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"GSK3511294","otherNames":["Depemokimab"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"GSK3511294","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.","primaryOutcome":{"measure":"Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks","timeFrame":"Up to Week 52","effectByArm":[{"arm":"GSK3511294","deltaMin":0.56,"sd":null},{"arm":"Placebo","deltaMin":1.08,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":129,"countries":["United States","Australia","Canada","Czechia","France","Hungary","Italy","Japan","Poland","Spain","Taiwan"]},"refs":{"pmids":["39248309"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":251},"commonTop":["Nasopharyngitis","COVID-19","Headache","Upper respiratory tract infection","Bronchitis"]}}